Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab.
Here, we report a case of paediatric beta-thalassaemia major patient who underwent unrelated T cell-non- depleted bone marrow transplantation and developed a complication of autoimmune haemolytic anaemia (AIHA) refractory to corticosteroid and intravenous immunoglobulin therapy. After this child received two doses (375 mg/m2/dose) of rituximab (anti-CD20 monoclonal antibody), his AIHA was resolved.
Hongeng
S
S
Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Tardtong
P
P
Worapongpaiboon
S
S
Ungkanont
A
A
Jootar
S
S
D000744:Anemia, Hemolytic, Autoimmune / Q000097:blood / Q000209:etiology* / Q000628:therapy*; D000753:Anemia, Refractory / Q000097:blood / Q000209:etiology* / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002675:Child, Preschool; D006801:Humans; D008297:Male; D000069283:Rituximab; D014184:Transplantation, Homologous; D017086:beta-Thalassemia / Q000628:therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab